$595m octreotide deal grabs Roche


Swiss drugmaker Roche has struck a $595 million (£390 million) deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth.

The active compound, octreotide, is already commercially available as an injection, marketed by Novartis under the name Sandostatin. The tablets are currently in Phase III trials against acromegaly, which is caused by the pituitary gland producing too much growth hormone. The two companies will subsequently look to commercialise the drug for the treatment of neuroendocrine tumours.

Roche will pay $65 million for worldwide marketing rights to the brand and make further payments of up to $530 million as milestones are passed.

Chiasma specialises in turning injectable drug formulations into viable oral equivalents.


Related Content

From molecules to medicines

9 April 2013 Premium contentFeature

news image

Turning an active drug molecule into a finished product requires a lot of chemistry, as Phillip Broadwith discovers

Business roundup

26 October 2011 Business

news image

Industry news, November 2011

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint